U.S. lifts pause on J&J vaccinations, clearing the way for shots to resume
The CDC and FDA lifted their pause on Johnson & Johnson vaccinations, clearing the way for states to resume shots despite the tiny risk of rare blood clots.
A federal advisory panel has recommended that immunizations with Johnson & Johnson’s COVID-19 vaccine be resumed despite a tiny risk of blood clots.
On a 10-4 vote, the Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices on Friday reaffirmed its earlier recommendation that the vaccine be used for people ages 18 and up.
The vote effectively ends a pause recommended April12 by experts at the CDC and the Food and Drug Administration. Their concern arose from six cases of a rare and perplexing clotting disorder seen among recipients of the single-shot vaccine. All six of those cases involved women between the ages of 18 and 48.
The blood clots were unusual because they were accompanies by a dangerously low level of platelets, the building blocks of blood clots.
The initial six cases rose to 15 when safety experts went back and reviewed records of adverse reactions to the vaccine. All of those cases were in women, and all but one of was under 50.
Even so, the panel said the risk was still tiny — effectively 1.9 cases per million people in the general population, or 7 cases per million women under 50.
The advisory panel rejected a a plan that would have explicitly called on women between the ages of 18 and 50 to “be aware” of the risk of the clotting disorder and make clear that they “may choose” another COVID-19 vaccine.
Panel members cautioned that such language might be seen as requiring these women to give explicit consent to taking the Johnson & Johnson shot, or that it might oblige vaccine clinics to carry alternative vaccines, thereby imposing logistical and other constraints that could hamper vaccination.
This story originally appeared in Los Angeles Times.